<DOC>
	<DOCNO>NCT00815893</DOCNO>
	<brief_summary>The objective study evaluate feasibility dexmedetomidine infusion oral cancer patient undergo awake fiberoptic nasal intubation . We hypothesize load dose intravenous dexmedetomidine awake fiberoptic nasal intubation oral cancer patient undergo general anesthesia provide adequate sedation analgesia without respiratory depression upper airway obstruction .</brief_summary>
	<brief_title>The Feasibility Dexmedetomidine Awake Fiberoptic Nasal Intubation</brief_title>
	<detailed_description>Case number : 60 , ASA I-III oral cancer patient limit mouth opening Patients randomly allocate three group , Dex group receive dexmedetomidine ( 1.0 mcg/kg ) infusion , Control group receive saline , Propofol group receive 1 % Propofol administrate usng effect-site TCI . Main outcome evaluate grade score present condition nasal intubation , post-intubation satisfaction . Other analysed parameter include airway obstruction , hemodynamic change , treatment hemodynamics response , consumption time intubation , amnesia level , postoperative adverse event . All outcome measurement classify score system .</detailed_description>
	<mesh_term>Propofol</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>Head neck cancer patient limit mouth open Undergoing awake fiberoptic nasal intubation elective surgery history severe bradycardia type AV block EKG heart failure liver cirrhosis thrombocytopenia coagulopathy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Dexmedetomidine</keyword>
	<keyword>Fiberoptic nasal intubation</keyword>
	<keyword>satisfaction</keyword>
</DOC>